“
“The dehydrogenation of methylcyclohexane (MCH) to toluene (TOL) for hydrogen production was theoretically and experimentally investigated

in a bimodal catalytic membrane reactor (CMR), that combined Pt/Al2O3 catalysts with a hydrogen-selective organosilica membrane prepared via sol-gel processing using bis(triethoxysilyl) ethane (BTESE). Effects of SNS-032 in vitro operating conditions on the membrane reactor performance were systematically investigated, and the experimental results were in good agreement with those calculated by a simulation model with a fitted catalyst loading. With H-2 extraction from the reaction stream to the permeate stream, MCH conversion at 250 degrees C was significantly increased beyond the equilibrium conversion of 0.44-0.86. Because of the high H-2 selectivity and permeance of BTESE-derived membranes, a H-2 flow with purity higher than 99.8% was obtained in the permeate stream, and the H-2 recovery ratio reached 0.99 in a pressurized reactor. A system that combined the CMR with a fixed-bed prereactor was proposed for MCH dehydrogenation.

(c) 2015 American Institute of Chemical Engineers AIChE J, 61: 1628-1638, 2015″
“P>Background\n\nPrevious reports have suggested that certain probiotics given PLX4032 clinical trial to mothers and children at risk of atopy halves the incidence of atopic dermatitis (AD) at 2 years of age.\n\nObjectives\n\nTo examine if probiotics given to pregnant women in a nonselected population could prevent atopic sensitization or allergic diseases during the child’s first 2 years.\n\nMethods\n\nIn a randomized, double-blind trial of children from a nonselected maternal population (ClinicalTrials.gov identifier: NCT00159523), women received probiotic milk or placebo from 36 weeks of gestation to 3 months postnatally during breastfeeding. The probiotic milk contained Lactobacillus rhamnosus GG, L. acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12. Children with an itchy rash for more than

4 weeks were assessed for AD. At 2 years of age, all children were assessed for atopic sensitization, AD, asthma and allergic rhinoconjunctivitis. The intention-to-treat (ITT) analysis was enabled by multiple imputations.\n\nResults\n\nFour hundred and fifteen pregnant women were computer randomized. At 2 years, 138 and 140 children in the probiotic and the placebo groups, respectively, were assessed. In the ITT analysis, the odds ratio Selleckchem GSK923295 (OR) for the cumulative incidence of AD was 0 center dot 51 in the probiotic group compared with the placebo [95% confidence interval (CI) 0 center dot 30-0 center dot 87; P = 0 center dot 013]. There were no significant effects on asthma (OR 0 center dot 68, 95% CI 0 center dot 26-1 center dot 80; P = 0 center dot 437) or atopic sensitization (OR 1 center dot 52, 95% CI 0 center dot 74-3 center dot 14; P = 0 center dot 254).\n\nConclusions\n\nProbiotics given to nonselected mothers reduced the cumulative incidence of AD, but had no effect on atopic sensitization.